Anti-Mouse OX40/CD134 Antibody (OX-86)
Based on 1 Customer Validation
Anti-Mouse OX40/CD134 Antibody (OX-86) is an anti-mouse OX40/CD134 IgG1 monoclonal antibody. Anti-Mouse OX40/CD134 Antibody (OX-86) can enhance the anti-tumor function of CD8+ T cells. Anti-Mouse OX40/CD134 Antibody (OX-86) can reverse immune suppression, enhance antigen presentation and T cell activation. Anti-Mouse OX40/CD134 Antibody (OX-86) can be used for research on cancer such as papilloma and leukemia.
For research use only. We do not sell to patients.
- Purity : ≥99.0%
- Molecular Weight:150 kDa
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
All Orexin Receptor (OX Receptor) Isoforms
More
Biological Activity
Description
Isotype
Rat IgG1 kappa
Recommend Isotype Controls
Species Reactivity
Mouse
IC50 & Target
OX40/CD134
In Vitro
Anti-Mouse OX40/CD134 Antibody (OX-86) (100 µg/mL, 5-7 days) upregulates the activation markers of DCs (CD40 and CD86) and reduces the expression of PD-L1 in SB28-OVA and EG7-OVA cells[3].
Anti-Mouse OX40/CD134 Antibody (OX-86) (10 µg/mL, 1 h) significantly enhances tumor cell apoptosis induced by tumor infiltrating lymphocytes (TILs)[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
Anti-Mouse OX40/CD134 Antibody (OX-86) (10 mg/kg, i.p., once a week, for 2 dose) significantly inhibits tumor growth combined with PEG-MTAP in DBA/2 mice bearing L1210 tumors[2].
Anti-Mouse OX40/CD134 Antibody (OX-86) (200 µg, i.p., on day 4, 7 and 10) significantly inhibits tumor growth in female C57BL/6 mice bearing SB28-OVA or EG7-OVA tumors[3].
Anti-Mouse OX40/CD134 Antibody (OX-86) (100 µg, i.p., twice a week, for 2 weeks) delays tumor growth and enhances CD8+ T cell function in C57BL/6 mice bearing MC38 tumors[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:1×105 TC-1 cells injected female C57BL/6 mice (6-8 weeks)[1]
-
Dosage:100 µg
-
Administration:Intraperitoneal injection (i.p.), twice a week
-
Result:Had a weak inhibitory effect on tumor growth.
-
Animal Model:5×104 L1210 cells injected DBA/2 mice (6-8 weeks)[2]
-
Dosage:10 mg/kg, combined with PEG-MTAP (50 mg/kg, s.c., 3 times a week, for 5 dose)
-
Administration:Intraperitoneal injection (i.p.), once a week, for 2 dose
-
Result:Significantly inhibited tumor volume.
-
Animal Model:1600 SB28-OVA cells or 25000 EG7-OVA cells injected female C57BL/6 mice (6-8 weeks)[3]
-
Dosage:200 µg
-
Administration:Intraperitoneal injection (i.p.), on day 4, 7 and 10
-
Result:Extended the survival period of mice (median survival period extended from 26 days to 31 days).
Reduced the proportion of Tregs and increased the number of memory T cells.
-
Animal Model:C57BL/6 mice bearing MC38/gp100 tumors[4]
-
Dosage:100 µg
-
Administration:Intraperitoneal injection (i.p.), twice a week, for 2 weeks
-
Result:Delayed tumor growth.
Enhanced CD8+ T cell function.
Gene ID
Accession
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Application
in vivo OX40 activation; in vitro OX40 activation; Western blot
Verified Bioactivity
-
Immobilized Mouse OX40 Protein, His Tag can bind Anti-Mouse OX40/CD134 Antibody (OX-86). The EC50 for this effect is 171 ng/mL.
Chemical Information
-
Appearance Liquid
-
Molecular Weight 150 kDa
-
Color Colorless to light yellow
-
SMILES
[Anti-Mouse OX40/CD134 Antibody (OX-86)]
-
Shipping
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
-
Data Sheet (263 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
[1]. Sun Z, et al. Developing an Effective Therapeutic HPV Vaccine to Eradicate Large Tumors by Genetically Fusing Xcl1 and Incorporating IL-9 as Molecular Adjuvants. Vaccines (Basel). 2025 Jan 9;13(1):49. [Content Brief]
[2]. Gjuka D, et al. Enzyme-mediated depletion of methylthioadenosine restores T cell function in MTAP-deficient tumors and reverses immunotherapy resistance. Cancer Cell. 2023 Oct 9;41(10):1774-1787.e9. [Content Brief]
[3]. Badillo-Godinez O, et al. Brain tumors induce immunoregulatory dendritic cells in draining lymph nodes that can be targeted by OX40 agonist treatment. J Immunother Cancer. 2025 May 19;13(5):e011548. [Content Brief]
[4]. Peng W, et al. Anti-OX40 Antibody Directly Enhances The Function of Tumor-Reactive CD8+ T Cells and Synergizes with PI3Kβ Inhibition in PTEN Loss Melanoma. Clin Cancer Res. 2019 Nov 1;25(21):6406-6416. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Anti-Mouse OX40/CD134 Antibody (OX-86) Related Classifications
HY-P990115 Related Classifications
Powered by Bioz